BeOne Medicines (BEIGF) – aksjekurser og nyheter

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia

Om BeOne Medicines

Administrerende direktørJohn Vincent Oyler | John Vincent Oyler

Ansatte12k

Grunnlagt28. okt. 2010

Hovedkontor-

Sektor-

Nettstedbeonemedicines.com

Alle verdier i USD	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	1,41 mrd.	1,50 mrd.	1,51 mrd.	1,71 mrd.
Varekostnad	196,51 mill.	142,42 mill.	167,22 mill.	174,53 mill.
Direkte driftskostnader	196,51 mill.	142,42 mill.	167,22 mill.	174,53 mill.
Utgifter til forskning og utvikling	523,66 mill.	615,42 mill.	541,22 mill.	612,28 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	529,00 mill.	555,29 mill.	555,10 mill.	593,21 mill.
Driftskostnader	1,05 mrd.	1,17 mrd.	1,10 mrd.	1,21 mrd.
Totale driftskostnader	1,25 mrd.	1,31 mrd.	1,26 mrd.	1,38 mrd.
Driftsinntekter	163,11 mill.	185,04 mill.	249,90 mill.	325,05 mill.
Andre ikke-operasjonelle inntekter	−4,76 mill.	4,16 mill.	14,54 mill.	−2,68 mill.
EBT inkludert uvanlige elementer	147,16 mill.	149,24 mill.	259,22 mill.	312,46 mill.
EBT uten uvanlige elementer	160,80 mill.	189,96 mill.	259,22 mill.	309,33 mill.
Kostnad for inntektsskatt	22,32 mill.	82,74 mill.	31,86 mill.	75,45 mill.
Faktisk avgiftssats	15,17 %	55,44 %	12,29 %	24,15 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	124,84 mill.	66,50 mill.	227,36 mill.	237,01 mill.
Netto fortjenestemargin	8,84 %	4,44 %	15,02 %	13,90 %
Resultat per aksje	1,09	0,58	1,96	2,05
Rente- og investeringsinntekter	13,79 mill.	32,37 mill.	27,66 mill.	27,90 mill.
Rentekostnader	−10,76 mill.	−32,47 mill.	−32,89 mill.	−39,74 mill.
Netto rentekostnader	3,03 mill.	−103,00k	−5,22 mill.	−11,84 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	198,86 mill.	219,47 mill.	289,30 mill.	363,97 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

Finance

Spør om hva som helst